Biotie Therapies - Company Announcement

Biotie announces topline data from an exploratory phase 2a study with SYN118 in Parkinson's disease

BIOTIE THERAPIES CORP.      STOCK EXCHANGE RELEASE       24 May 2011, at 9.00
a.m.

Biotie announces topline data from an exploratory phase 2a study with SYN118 in
Parkinson's disease

Biotie Therapies Corp., a development stage company focused on diseases of the
central nervous system, today announced results from an exploratory phase 2a
study of its HPPD inhibitor SYN118 in Parkinson's disease (PD). These data do
not show a significant improvement in measures of PD motor function when
compared to placebo. Biotie will consider development options for the compound
and will announce further plans later in the year.

SYN118 is subject to an option agreement with UCB as part of a broader
partnership.  Biotie does not expect UCB to exercise its option to license the
compound based on the now published data. The UCB collaboration also includes
Biotie's novel adenosine A2a receptor antagonist, SYN115, which is in phase 2b
development for PD targeting a mechanism of action different from that of SYN
118 and which has been shown to significantly modulate the off-time (time when
Parkinson's patients  have rigidity and other associated problems) without an
increase in dyskinesias."We are disappointed that this novel approach to treating Parkinson's patients
at an advanced stage of the disease, where levodopa is no longer controlling
symptoms, was not successful. However, today's results have no impact on the
development of our lead PD product, SYN115, and our agreement with UCB around
it. There remains a need for new medicines to treat PD that work through
mechanisms different to those of existing drugs, and we remain committed to
their development" said Timo Veromaa, President and CEO of Biotie Therapies.

In Turku, 24 May, 2011

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Dr. Stephen Bandak, Chief Medical Officer
tel. +1 650 296 0946
email:stephen.bandak@biotie.com

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail:virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

About the Phase 2a study in Parkinson's disease

In this exploratory study conducted in France and the Czech Republic, 127
levodopa-treated PD patients with wearing-off motor fluctuations were randomized
to receive either SYN118 or placebo added on their existing  anti-Parkinson
medications for 8 weeks.  The drug was well tolerated but there was no
appreciable difference between SYN118 and placebo in the outcomes of highest
interest in this study which were: UPDRS part III (motor function) before and
approximately 2 hours after the patients' usual anti-Parkinson medication i.e.
when in the "off" and "on" states respectively and in daily time in "off" and in"on" as recorded by the patients using home diaries.

About SYN118

SYN118 is a potent and selective inhibitor of 4-hydroxyphenylpyruvate
dioxygenase (HPPD). HPPD is an enzyme in the primary pathway responsible for the
breakdown of tyrosine, the precursor of the neurotransmitter dopamine. This
novel point of intervention has been thought to offer the potential to induce a
sustained increase in dopamine synthesis in specific regions of the brain
resulting in clinical benefit.

SYN118 was discovered by AstraZeneca and developed by Syngenta and their partner
Swedish Orphan for the treatment of hereditary tyrosinemia type 1. In 2007,
Biotie (formerly Synosia) obtained rights from Syngenta to develop and
commercialize SYN118 in non-orphan diseases.

Swedish Orphan International (SOI) markets the compound in Europe, the United
States, Australia and Russia for the treatment of hereditary tyrosinemia type
1, under the brand name Orfadin®. The development program of SOI has generated
over 5,000 patient years of clinical and market experience to date.

About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (Parkinson's disease,
Alzheimer's disease and other cognitive disorders, bipolar disorder, and alcohol
and drug dependence) and inflammatory diseases (rheumatoid arthritis, psoriasis,
chronic obstructive pulmonary disease and others). It has several innovative
small molecule and biological drug candidates at different stages of clinical
development. Biotie's products address diseases with high unmet medical need and
significant market potential.

Partnerships with top/tier pharmaceutical partners are in place for several
programs  as well as a strategic collaboration with UCB Pharma S.A. Biotie's
most advanced product, nalmefene for alcohol dependence, is currently in Phase
3 clinical development by licensing partner H. Lundbeck A/S.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.




[HUG#1518106]